Senseonics Q2 2026 earnings: Revenue doubles while losses widen

Senseonics (NASDAQ: SENS) reported second-quarter 2026 revenue of $14.5 million, up approximately 120% from $6.6 million a year earlier, while diluted loss per share widened to $0.63 from $0.36. Gross margin improved to roughly 59%, but higher commercial integration and product-development spending pushed the net loss to $36.7 million.

Core financial results

The quarter combined rapid revenue growth and a higher gross margin with a materially larger operating loss. Gross profit grew faster than revenue, but the increase was outweighed by significantly higher selling, general and administrative expenses and increased research and development spending.

Business and geographic performance

The United States accounted for most of the quarterly growth. Revenue outside the U.S. increased more slowly as European tender timing affected results during the transition from Ascensia.

Senseonics said U.S. quarterly shipment volume reached a company record, while active prescribers increased approximately 130% from the prior-year period. Direct-to-consumer activity became the largest source of new patients, and the company also reported continued adoption of Eversense 365 with the twiist Automated Insulin Delivery system.

Eon Care expanded to more than 90 nurses and handled approximately 40% of Eversense insertion procedures. Senseonics remains on track for its year-end objective of 100 nurses. In Europe, the company completed the commercial transition from Ascensia in June and brought sales and marketing operations in Germany, Italy, Spain, and Sweden in-house.

Commercial expansion lifted revenue and margin, but spending deepened losses

Senseonics added approximately $5.4 million of gross profit year over year, but combined R&D and SG&A expenses increased by approximately $27.1 million. As a result, the operating loss widened by approximately $21.7 million despite the roughly 12-percentage-point improvement in gross margin.

SG&A increased primarily because of commercial integration and the European transition. R&D spending rose as the company funded the Gemini clinical program and continued developing Freedom. These investments help explain why stronger sales and unit economics did not yet produce operating leverage.

Liquidity and balance sheet

As of June 30, 2026, Senseonics held approximately $143.0 million across cash and cash equivalents, restricted cash, and short-term investments. This consisted of $44.8 million of cash and cash equivalents, $0.3 million of restricted cash, and $97.9 million of short-term investments.

The company reported $55.5 million of outstanding indebtedness, including accrued interest. During the quarter, it raised more than $100 million, including approximately $90 million in equity proceeds, and expanded its Hercules Capital facility to provide up to $140 million of capacity.

Financial guidance

Senseonics raised both its full-year revenue and gross-margin forecasts. Each endpoint of the revenue range increased by $2 million, while each endpoint of the gross-margin range increased by three percentage points.

The outlook incorporates the Eversense 365 rollout outside the United States, planned direct-to-consumer marketing investment, other sales initiatives, and the use of Eversense 365 patient assistance programs. Management expects European revenue timing to normalize in the third and fourth quarters and continues to expect Europe to contribute approximately 20% of full-year revenue.

Risks investors should monitor

• Expenses remain high relative to gross profit. Quarterly SG&A alone was more than double revenue, and further commercial expansion may keep operating losses elevated unless revenue begins to scale faster than spending.
• European results depend on transition execution and tender timing. Revenue outside the U.S. grew only approximately 12% during the quarter, and management’s outlook assumes the timing effects will normalize later in 2026.
• Commercial growth requires continued network expansion. Eon Care’s progress toward 100 nurses and the productivity of direct-to-consumer and healthcare-provider channels will influence whether U.S. momentum continues.
• Development programs add spending and execution risk. Gemini clinical work and Freedom development contributed to higher R&D expenses before those programs generated disclosed commercial revenue.
• Ongoing losses may consume liquidity. The balance sheet was strengthened through equity financing and additional debt capacity, but the company still reported a $36.7 million quarterly net loss and $55.5 million of indebtedness.

Summary

Senseonics’ second-quarter 2026 results showed faster Eversense commercialization, led by the United States, along with a substantial improvement in gross margin. However, the commercial buildout, European integration, and development programs caused expenses and losses to rise much faster than gross profit. The main items to monitor are whether U.S. growth remains durable, European revenue timing normalizes, and the expanded commercial platform begins to produce operating leverage.